#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0186] Virus neutralization assays are useful for detection of antibodies that not only specifically bind to the pathogen, but also neutralize the function of the virus.
1-1	0-1	[	_	_	
1-2	1-5	0186	_	_	
1-3	5-6	]	_	_	
1-4	7-12	Virus	_	_	
1-5	13-27	neutralization	_	_	
1-6	28-34	assays	_	_	
1-7	35-38	are	_	_	
1-8	39-45	useful	_	_	
1-9	46-49	for	_	_	
1-10	50-59	detection	_	_	
1-11	60-62	of	_	_	
1-12	63-73	antibodies	_	_	
1-13	74-78	that	_	_	
1-14	79-82	not	_	_	
1-15	83-87	only	_	_	
1-16	88-100	specifically	_	_	
1-17	101-105	bind	_	_	
1-18	106-108	to	_	_	
1-19	109-112	the	_	_	
1-20	113-121	pathogen	_	_	
1-21	121-122	,	_	_	
1-22	123-126	but	_	_	
1-23	127-131	also	_	_	
1-24	132-142	neutralize	_	_	
1-25	143-146	the	_	_	
1-26	147-155	function	_	_	
1-27	156-158	of	_	_	
1-28	159-162	the	_	_	
1-29	163-168	virus	_	_	
1-30	168-169	.	_	_	

#Text=These assays are typically based on detection of antibodies in the sera of immunized animal and analysis of these antibodies for their capacity to inhibit viral growth in tissue culture cells.
2-1	170-175	These	_	_	
2-2	176-182	assays	_	_	
2-3	183-186	are	_	_	
2-4	187-196	typically	_	_	
2-5	197-202	based	_	_	
2-6	203-205	on	_	_	
2-7	206-215	detection	_	_	
2-8	216-218	of	_	_	
2-9	219-229	antibodies	_	_	
2-10	230-232	in	_	_	
2-11	233-236	the	_	_	
2-12	237-241	sera	_	_	
2-13	242-244	of	_	_	
2-14	245-254	immunized	_	_	
2-15	255-261	animal	_	_	
2-16	262-265	and	_	_	
2-17	266-274	analysis	_	_	
2-18	275-277	of	_	_	
2-19	278-283	these	_	_	
2-20	284-294	antibodies	_	_	
2-21	295-298	for	_	_	
2-22	299-304	their	_	_	
2-23	305-313	capacity	_	_	
2-24	314-316	to	_	_	
2-25	317-324	inhibit	_	_	
2-26	325-330	viral	_	_	
2-27	331-337	growth	_	_	
2-28	338-340	in	_	_	
2-29	341-347	tissue	_	_	
2-30	348-355	culture	_	_	
2-31	356-361	cells	_	_	
2-32	361-362	.	_	_	

#Text=Such assays are known to those skilled in the art.
3-1	363-367	Such	_	_	
3-2	368-374	assays	_	_	
3-3	375-378	are	_	_	
3-4	379-384	known	_	_	
3-5	385-387	to	_	_	
3-6	388-393	those	_	_	
3-7	394-401	skilled	_	_	
3-8	402-404	in	_	_	
3-9	405-408	the	_	_	
3-10	409-412	art	_	_	
3-11	412-413	.	_	_	

#Text=One example of a virus neutralization assay is described by Dolin R (J.
4-1	414-417	One	_	_	
4-2	418-425	example	_	_	
4-3	426-428	of	_	_	
4-4	429-430	a	_	_	
4-5	431-436	virus	_	_	
4-6	437-451	neutralization	_	_	
4-7	452-457	assay	_	_	
4-8	458-460	is	_	_	
4-9	461-470	described	_	_	
4-10	471-473	by	_	_	
4-11	474-479	Dolin	_	_	
4-12	480-481	R	_	_	
4-13	482-483	(	_	_	
4-14	483-484	J	_	_	
4-15	484-485	.	_	_	

#Text=Infect.
5-1	486-492	Infect	_	_	
5-2	492-493	.	_	_	

#Text=Dis. 1995, 172:1175-83).
6-1	494-497	Dis	_	_	
6-2	497-498	.	_	_	
6-3	499-503	1995	_	_	
6-4	503-504	,	_	_	
6-5	505-508	172	_	_	
6-6	508-509	:	_	_	
6-7	509-513	1175	_	_	
6-8	513-514	-	_	_	
6-9	514-516	83	_	_	
6-10	516-517	)	_	_	
6-11	517-518	.	_	_	

#Text=Virus neutralization assays provide means to screen for antigens that also provide protective immunity.
#Text=[0187] In some embodiments, shuffled antigens are screened for their capacity to induce T cell activation in vivo.
7-1	519-524	Virus	_	_	
7-2	525-539	neutralization	_	_	
7-3	540-546	assays	_	_	
7-4	547-554	provide	_	_	
7-5	555-560	means	_	_	
7-6	561-563	to	_	_	
7-7	564-570	screen	_	_	
7-8	571-574	for	_	_	
7-9	575-583	antigens	_	_	
7-10	584-588	that	_	_	
7-11	589-593	also	_	_	
7-12	594-601	provide	_	_	
7-13	602-612	protective	_	_	
7-14	613-621	immunity	_	_	
7-15	621-622	.	_	_	
7-16	623-624	[	_	_	
7-17	624-628	0187	_	_	
7-18	628-629	]	_	_	
7-19	630-632	In	_	_	
7-20	633-637	some	_	_	
7-21	638-649	embodiments	_	_	
7-22	649-650	,	_	_	
7-23	651-659	shuffled	_	_	
7-24	660-668	antigens	_	_	
7-25	669-672	are	_	_	
7-26	673-681	screened	_	_	
7-27	682-685	for	_	_	
7-28	686-691	their	_	_	
7-29	692-700	capacity	_	_	
7-30	701-703	to	_	_	
7-31	704-710	induce	_	_	
7-32	711-712	T	_	_	
7-33	713-717	cell	_	_	
7-34	718-728	activation	_	_	
7-35	729-731	in	_	_	
7-36	732-736	vivo	_	_	
7-37	736-737	.	_	_	

#Text=More specifically, peripheral blood mononuclear cells or spleen cells from injected mice can be isolated and the capacity of cytotoxic T lymphocytes to lyse infected, autologous target cells is studied.
8-1	738-742	More	_	_	
8-2	743-755	specifically	_	_	
8-3	755-756	,	_	_	
8-4	757-767	peripheral	_	_	
8-5	768-773	blood	_	_	
8-6	774-785	mononuclear	_	_	
8-7	786-791	cells	_	_	
8-8	792-794	or	_	_	
8-9	795-801	spleen	_	_	
8-10	802-807	cells	_	_	
8-11	808-812	from	_	_	
8-12	813-821	injected	_	_	
8-13	822-826	mice	_	_	
8-14	827-830	can	_	_	
8-15	831-833	be	_	_	
8-16	834-842	isolated	_	_	
8-17	843-846	and	_	_	
8-18	847-850	the	_	_	
8-19	851-859	capacity	_	_	
8-20	860-862	of	_	_	
8-21	863-872	cytotoxic	_	_	
8-22	873-874	T	_	_	
8-23	875-886	lymphocytes	_	_	
8-24	887-889	to	_	_	
8-25	890-894	lyse	_	_	
8-26	895-903	infected	_	_	
8-27	903-904	,	_	_	
8-28	905-915	autologous	_	_	
8-29	916-922	target	_	_	
8-30	923-928	cells	_	_	
8-31	929-931	is	_	_	
8-32	932-939	studied	_	_	
8-33	939-940	.	_	_	

#Text=The spleen cells can be reactivated with the specific antigen in vitro.
9-1	941-944	The	_	_	
9-2	945-951	spleen	_	_	
9-3	952-957	cells	_	_	
9-4	958-961	can	_	_	
9-5	962-964	be	_	_	
9-6	965-976	reactivated	_	_	
9-7	977-981	with	_	_	
9-8	982-985	the	_	_	
9-9	986-994	specific	_	_	
9-10	995-1002	antigen	_	_	
9-11	1003-1005	in	_	_	
9-12	1006-1011	vitro	_	_	
9-13	1011-1012	.	_	_	

#Text=In addition, T helper cell activation and differentiation is analyzed by measuring cell proliferation or production of T.sub.H1 (IL-2 and IFN-.gamma.) and T.sub.H2 (IL-4 and IL-5) cytokines by ELISA and directly in CD4.sup.+ T cells by cytoplasmic cytokine staining and flow cytometry.
10-1	1013-1015	In	_	_	
10-2	1016-1024	addition	_	_	
10-3	1024-1025	,	_	_	
10-4	1026-1027	T	_	_	
10-5	1028-1034	helper	_	_	
10-6	1035-1039	cell	_	_	
10-7	1040-1050	activation	_	_	
10-8	1051-1054	and	_	_	
10-9	1055-1070	differentiation	_	_	
10-10	1071-1073	is	_	_	
10-11	1074-1082	analyzed	_	_	
10-12	1083-1085	by	_	_	
10-13	1086-1095	measuring	_	_	
10-14	1096-1100	cell	_	_	
10-15	1101-1114	proliferation	_	_	
10-16	1115-1117	or	_	_	
10-17	1118-1128	production	_	_	
10-18	1129-1131	of	_	_	
10-19	1132-1140	T.sub.H1	_	_	
10-20	1141-1142	(	_	_	
10-21	1142-1144	IL	_	_	
10-22	1144-1145	-	_	_	
10-23	1145-1146	2	_	_	
10-24	1147-1150	and	_	_	
10-25	1151-1154	IFN	_	_	
10-26	1154-1155	-	_	_	
10-27	1155-1156	.	_	_	
10-28	1156-1161	gamma	_	_	
10-29	1161-1162	.	_	_	
10-30	1162-1163	)	_	_	
10-31	1164-1167	and	_	_	
10-32	1168-1176	T.sub.H2	_	_	
10-33	1177-1178	(	_	_	
10-34	1178-1180	IL	_	_	
10-35	1180-1181	-	_	_	
10-36	1181-1182	4	_	_	
10-37	1183-1186	and	_	_	
10-38	1187-1189	IL	_	_	
10-39	1189-1190	-	_	_	
10-40	1190-1191	5	_	_	
10-41	1191-1192	)	_	_	
10-42	1193-1202	cytokines	_	_	
10-43	1203-1205	by	_	_	
10-44	1206-1211	ELISA	_	_	
10-45	1212-1215	and	_	_	
10-46	1216-1224	directly	_	_	
10-47	1225-1227	in	_	_	
10-48	1228-1231	CD4	_	_	
10-49	1231-1232	.	_	_	
10-50	1232-1235	sup	_	_	
10-51	1235-1236	.	_	_	
10-52	1236-1237	+	_	_	
10-53	1238-1239	T	_	_	
10-54	1240-1245	cells	_	_	
10-55	1246-1248	by	_	_	
10-56	1249-1260	cytoplasmic	_	_	
10-57	1261-1269	cytokine	_	_	
10-58	1270-1278	staining	_	_	
10-59	1279-1282	and	_	_	
10-60	1283-1287	flow	_	_	
10-61	1288-1297	cytometry	_	_	
10-62	1297-1298	.	_	_	

#Text=Based on the cytokine production profile, one can also screen for alterations in the capacity of the antigens to direct T.sub.H1/TH.sup.2 differentiation (as evidenced, for example, by changes in ratios of IL-4/IFN-.gamma., IL-4/IL-2, IL-5/IFN-.gamma., IL-5/IL-2, IL-13/IFN-.gamma., IL-13/IL-2).
11-1	1299-1304	Based	_	_	
11-2	1305-1307	on	_	_	
11-3	1308-1311	the	_	_	
11-4	1312-1320	cytokine	_	_	
11-5	1321-1331	production	_	_	
11-6	1332-1339	profile	_	_	
11-7	1339-1340	,	_	_	
11-8	1341-1344	one	_	_	
11-9	1345-1348	can	_	_	
11-10	1349-1353	also	_	_	
11-11	1354-1360	screen	_	_	
11-12	1361-1364	for	_	_	
11-13	1365-1376	alterations	_	_	
11-14	1377-1379	in	_	_	
11-15	1380-1383	the	_	_	
11-16	1384-1392	capacity	_	_	
11-17	1393-1395	of	_	_	
11-18	1396-1399	the	_	_	
11-19	1400-1408	antigens	_	_	
11-20	1409-1411	to	_	_	
11-21	1412-1418	direct	_	_	
11-22	1419-1427	T.sub.H1	_	_	
11-23	1427-1428	/	_	_	
11-24	1428-1434	TH.sup	_	_	
11-25	1434-1436	.2	_	_	
11-26	1437-1452	differentiation	_	_	
11-27	1453-1454	(	_	_	
11-28	1454-1456	as	_	_	
11-29	1457-1466	evidenced	_	_	
11-30	1466-1467	,	_	_	
11-31	1468-1471	for	_	_	
11-32	1472-1479	example	_	_	
11-33	1479-1480	,	_	_	
11-34	1481-1483	by	_	_	
11-35	1484-1491	changes	_	_	
11-36	1492-1494	in	_	_	
11-37	1495-1501	ratios	_	_	
11-38	1502-1504	of	_	_	
11-39	1505-1507	IL	_	_	
11-40	1507-1508	-	_	_	
11-41	1508-1509	4	_	_	
11-42	1509-1510	/	_	_	
11-43	1510-1513	IFN	_	_	
11-44	1513-1514	-	_	_	
11-45	1514-1515	.	_	_	
11-46	1515-1520	gamma	_	_	
11-47	1520-1521	.	_	_	
11-48	1521-1522	,	_	_	
11-49	1523-1525	IL	_	_	
11-50	1525-1526	-	_	_	
11-51	1526-1527	4	_	_	
11-52	1527-1528	/	_	_	
11-53	1528-1530	IL	_	_	
11-54	1530-1531	-	_	_	
11-55	1531-1532	2	_	_	
11-56	1532-1533	,	_	_	
11-57	1534-1536	IL	_	_	
11-58	1536-1537	-	_	_	
11-59	1537-1538	5	_	_	
11-60	1538-1539	/	_	_	
11-61	1539-1542	IFN	_	_	
11-62	1542-1543	-	_	_	
11-63	1543-1544	.	_	_	
11-64	1544-1549	gamma	_	_	
11-65	1549-1550	.	_	_	
11-66	1550-1551	,	_	_	
11-67	1552-1554	IL	_	_	
11-68	1554-1555	-	_	_	
11-69	1555-1556	5	_	_	
11-70	1556-1557	/	_	_	
11-71	1557-1559	IL	_	_	
11-72	1559-1560	-	_	_	
11-73	1560-1561	2	_	_	
11-74	1561-1562	,	_	_	
11-75	1563-1565	IL	_	_	
11-76	1565-1566	-	_	_	
11-77	1566-1568	13	_	_	
11-78	1568-1569	/	_	_	
11-79	1569-1572	IFN	_	_	
11-80	1572-1573	-	_	_	
11-81	1573-1574	.	_	_	
11-82	1574-1579	gamma	_	_	
11-83	1579-1580	.	_	_	
11-84	1580-1581	,	_	_	
11-85	1582-1584	IL	_	_	
11-86	1584-1585	-	_	_	
11-87	1585-1587	13	_	_	
11-88	1587-1588	/	_	_	
11-89	1588-1590	IL	_	_	
11-90	1590-1591	-	_	_	
11-91	1591-1592	2	_	_	
11-92	1592-1593	)	_	_	
11-93	1593-1594	.	_	_	

#Text=The analysis of the T cell activation induced by the antigen variants is a very useful screening method, because potent activation of specific T cells in vivo correlates to induction of protective immunity.
#Text=[0188] The frequency of antigen-specific CD8.sup.+ T cells in vivo can also be directly analyzed using tetramers of MHC class I molecules expressing specific peptides derived from the corresponding pathogen antigens (Ogg and McMichael, Curr.
12-1	1595-1598	The	_	_	
12-2	1599-1607	analysis	_	_	
12-3	1608-1610	of	_	_	
12-4	1611-1614	the	_	_	
12-5	1615-1616	T	_	_	
12-6	1617-1621	cell	_	_	
12-7	1622-1632	activation	_	_	
12-8	1633-1640	induced	_	_	
12-9	1641-1643	by	_	_	
12-10	1644-1647	the	_	_	
12-11	1648-1655	antigen	_	_	
12-12	1656-1664	variants	_	_	
12-13	1665-1667	is	_	_	
12-14	1668-1669	a	_	_	
12-15	1670-1674	very	_	_	
12-16	1675-1681	useful	_	_	
12-17	1682-1691	screening	_	_	
12-18	1692-1698	method	_	_	
12-19	1698-1699	,	_	_	
12-20	1700-1707	because	_	_	
12-21	1708-1714	potent	_	_	
12-22	1715-1725	activation	_	_	
12-23	1726-1728	of	_	_	
12-24	1729-1737	specific	_	_	
12-25	1738-1739	T	_	_	
12-26	1740-1745	cells	_	_	
12-27	1746-1748	in	_	_	
12-28	1749-1753	vivo	_	_	
12-29	1754-1764	correlates	_	_	
12-30	1765-1767	to	_	_	
12-31	1768-1777	induction	_	_	
12-32	1778-1780	of	_	_	
12-33	1781-1791	protective	_	_	
12-34	1792-1800	immunity	_	_	
12-35	1800-1801	.	_	_	
12-36	1802-1803	[	_	_	
12-37	1803-1807	0188	_	_	
12-38	1807-1808	]	_	_	
12-39	1809-1812	The	_	_	
12-40	1813-1822	frequency	_	_	
12-41	1823-1825	of	_	_	
12-42	1826-1842	antigen-specific	_	_	
12-43	1843-1846	CD8	_	_	
12-44	1846-1847	.	_	_	
12-45	1847-1850	sup	_	_	
12-46	1850-1851	.	_	_	
12-47	1851-1852	+	_	_	
12-48	1853-1854	T	_	_	
12-49	1855-1860	cells	_	_	
12-50	1861-1863	in	_	_	
12-51	1864-1868	vivo	_	_	
12-52	1869-1872	can	_	_	
12-53	1873-1877	also	_	_	
12-54	1878-1880	be	_	_	
12-55	1881-1889	directly	_	_	
12-56	1890-1898	analyzed	_	_	
12-57	1899-1904	using	_	_	
12-58	1905-1914	tetramers	_	_	
12-59	1915-1917	of	_	_	
12-60	1918-1921	MHC	_	_	
12-61	1922-1927	class	_	_	
12-62	1928-1929	I	_	_	
12-63	1930-1939	molecules	_	_	
12-64	1940-1950	expressing	_	_	
12-65	1951-1959	specific	_	_	
12-66	1960-1968	peptides	_	_	
12-67	1969-1976	derived	_	_	
12-68	1977-1981	from	_	_	
12-69	1982-1985	the	_	_	
12-70	1986-1999	corresponding	_	_	
12-71	2000-2008	pathogen	_	_	
12-72	2009-2017	antigens	_	_	
12-73	2018-2019	(	_	_	
12-74	2019-2022	Ogg	_	_	
12-75	2023-2026	and	_	_	
12-76	2027-2036	McMichael	_	_	
12-77	2036-2037	,	_	_	
12-78	2038-2042	Curr	_	_	
12-79	2042-2043	.	_	_	

#Text=Opin.
13-1	2044-2048	Opin	_	_	
13-2	2048-2049	.	_	_	

#Text=Immunol. 1998, 10:393-6; Altman et al., Science 1996, 274:94-6).
14-1	2050-2057	Immunol	_	_	
14-2	2057-2058	.	_	_	
14-3	2059-2063	1998	_	_	
14-4	2063-2064	,	_	_	
14-5	2065-2067	10	_	_	
14-6	2067-2068	:	_	_	
14-7	2068-2071	393	_	_	
14-8	2071-2072	-	_	_	
14-9	2072-2073	6	_	_	
14-10	2073-2074	;	_	_	
14-11	2075-2081	Altman	_	_	
14-12	2082-2084	et	_	_	
14-13	2085-2087	al	_	_	
14-14	2087-2088	.	_	_	
14-15	2088-2089	,	_	_	
14-16	2090-2097	Science	_	_	
14-17	2098-2102	1996	_	_	
14-18	2102-2103	,	_	_	
14-19	2104-2107	274	_	_	
14-20	2107-2108	:	_	_	
14-21	2108-2110	94	_	_	
14-22	2110-2111	-	_	_	
14-23	2111-2112	6	_	_	
14-24	2112-2113	)	_	_	
14-25	2113-2114	.	_	_	

#Text=The binding of the tetramers can be detected using flow cytometry, and will provide information about the efficacy of the shuffled antigens to induce activation of specific T cells.
15-1	2115-2118	The	_	_	
15-2	2119-2126	binding	_	_	
15-3	2127-2129	of	_	_	
15-4	2130-2133	the	_	_	
15-5	2134-2143	tetramers	_	_	
15-6	2144-2147	can	_	_	
15-7	2148-2150	be	_	_	
15-8	2151-2159	detected	_	_	
15-9	2160-2165	using	_	_	
15-10	2166-2170	flow	_	_	
15-11	2171-2180	cytometry	_	_	
15-12	2180-2181	,	_	_	
15-13	2182-2185	and	_	_	
15-14	2186-2190	will	_	_	
15-15	2191-2198	provide	_	_	
15-16	2199-2210	information	_	_	
15-17	2211-2216	about	_	_	
15-18	2217-2220	the	_	_	
15-19	2221-2229	efficacy	_	_	
15-20	2230-2232	of	_	_	
15-21	2233-2236	the	_	_	
15-22	2237-2245	shuffled	_	_	
15-23	2246-2254	antigens	_	_	
15-24	2255-2257	to	_	_	
15-25	2258-2264	induce	_	_	
15-26	2265-2275	activation	_	_	
15-27	2276-2278	of	_	_	
15-28	2279-2287	specific	_	_	
15-29	2288-2289	T	_	_	
15-30	2290-2295	cells	_	_	
15-31	2295-2296	.	_	_	

#Text=For example, flow cytometry and tetramer stainings provide an efficient method of identifying T cells that are specific to a given antigen or peptide.
16-1	2297-2300	For	_	_	
16-2	2301-2308	example	_	_	
16-3	2308-2309	,	_	_	
16-4	2310-2314	flow	_	_	
16-5	2315-2324	cytometry	_	_	
16-6	2325-2328	and	_	_	
16-7	2329-2337	tetramer	_	_	
16-8	2338-2347	stainings	_	_	
16-9	2348-2355	provide	_	_	
16-10	2356-2358	an	_	_	
16-11	2359-2368	efficient	_	_	
16-12	2369-2375	method	_	_	
16-13	2376-2378	of	_	_	
16-14	2379-2390	identifying	_	_	
16-15	2391-2392	T	_	_	
16-16	2393-2398	cells	_	_	
16-17	2399-2403	that	_	_	
16-18	2404-2407	are	_	_	
16-19	2408-2416	specific	_	_	
16-20	2417-2419	to	_	_	
16-21	2420-2421	a	_	_	
16-22	2422-2427	given	_	_	
16-23	2428-2435	antigen	_	_	
16-24	2436-2438	or	_	_	
16-25	2439-2446	peptide	_	_	
16-26	2446-2447	.	_	_	

#Text=Another method involves panning using plates coated with tetramers with the specific peptides.
17-1	2448-2455	Another	*[1]	18-1[2_1]	
17-2	2456-2462	method	*[1]	_	
17-3	2463-2471	involves	*[1]	_	
17-4	2472-2479	panning	*[1]	_	
17-5	2480-2485	using	*[1]	_	
17-6	2486-2492	plates	*[1]	_	
17-7	2493-2499	coated	*[1]	_	
17-8	2500-2504	with	*[1]	_	
17-9	2505-2514	tetramers	*[1]	_	
17-10	2515-2519	with	*[1]	_	
17-11	2520-2523	the	*[1]	_	
17-12	2524-2532	specific	*[1]	_	
17-13	2533-2541	peptides	*[1]	_	
17-14	2541-2542	.	*[1]	_	

#Text=This method allows large numbers of cells to be handled in a short time, but the method only selects for highest expression levels.
18-1	2543-2547	This	*[2]	_	
18-2	2548-2554	method	*[2]	_	
18-3	2555-2561	allows	_	_	
18-4	2562-2567	large	_	_	
18-5	2568-2575	numbers	_	_	
18-6	2576-2578	of	_	_	
18-7	2579-2584	cells	_	_	
18-8	2585-2587	to	_	_	
18-9	2588-2590	be	_	_	
18-10	2591-2598	handled	_	_	
18-11	2599-2601	in	_	_	
18-12	2602-2603	a	_	_	
18-13	2604-2609	short	_	_	
18-14	2610-2614	time	_	_	
18-15	2614-2615	,	_	_	
18-16	2616-2619	but	_	_	
18-17	2620-2623	the	_	_	
18-18	2624-2630	method	_	_	
18-19	2631-2635	only	_	_	
18-20	2636-2643	selects	_	_	
18-21	2644-2647	for	_	_	
18-22	2648-2655	highest	_	_	
18-23	2656-2666	expression	_	_	
18-24	2667-2673	levels	_	_	
18-25	2673-2674	.	_	_	

#Text=The higher the frequency of antigen-specific T cells in vivo is, the more efficient the immunization has been, enabling identification of the antigen variants that have the most potent capacity to induce protective immune responses.
19-1	2675-2678	The	_	_	
19-2	2679-2685	higher	_	_	
19-3	2686-2689	the	_	_	
19-4	2690-2699	frequency	_	_	
19-5	2700-2702	of	_	_	
19-6	2703-2719	antigen-specific	_	_	
19-7	2720-2721	T	_	_	
19-8	2722-2727	cells	_	_	
19-9	2728-2730	in	_	_	
19-10	2731-2735	vivo	_	_	
19-11	2736-2738	is	_	_	
19-12	2738-2739	,	_	_	
19-13	2740-2743	the	_	_	
19-14	2744-2748	more	_	_	
19-15	2749-2758	efficient	_	_	
19-16	2759-2762	the	_	_	
19-17	2763-2775	immunization	_	_	
19-18	2776-2779	has	_	_	
19-19	2780-2784	been	_	_	
19-20	2784-2785	,	_	_	
19-21	2786-2794	enabling	_	_	
19-22	2795-2809	identification	_	_	
19-23	2810-2812	of	_	_	
19-24	2813-2816	the	_	_	
19-25	2817-2824	antigen	_	_	
19-26	2825-2833	variants	_	_	
19-27	2834-2838	that	_	_	
19-28	2839-2843	have	_	_	
19-29	2844-2847	the	_	_	
19-30	2848-2852	most	_	_	
19-31	2853-2859	potent	_	_	
19-32	2860-2868	capacity	_	_	
19-33	2869-2871	to	_	_	
19-34	2872-2878	induce	_	_	
19-35	2879-2889	protective	_	_	
19-36	2890-2896	immune	_	_	
19-37	2897-2906	responses	_	_	
19-38	2906-2907	.	_	_	

#Text=These studies are particularly useful when conducted in monkeys, or other primates, because the MHC class I molecules of humans mimic those of other primates more closely than those of mice.
#Text=[0189] Measurement of the activation of antigen presenting cells (APC) in response to immunization by antigen variants is another useful screening method.
20-1	2908-2913	These	_	_	
20-2	2914-2921	studies	_	_	
20-3	2922-2925	are	_	_	
20-4	2926-2938	particularly	_	_	
20-5	2939-2945	useful	_	_	
20-6	2946-2950	when	_	_	
20-7	2951-2960	conducted	_	_	
20-8	2961-2963	in	_	_	
20-9	2964-2971	monkeys	_	_	
20-10	2971-2972	,	_	_	
20-11	2973-2975	or	_	_	
20-12	2976-2981	other	_	_	
20-13	2982-2990	primates	_	_	
20-14	2990-2991	,	_	_	
20-15	2992-2999	because	_	_	
20-16	3000-3003	the	_	_	
20-17	3004-3007	MHC	_	_	
20-18	3008-3013	class	_	_	
20-19	3014-3015	I	_	_	
20-20	3016-3025	molecules	_	_	
20-21	3026-3028	of	_	_	
20-22	3029-3035	humans	_	_	
20-23	3036-3041	mimic	_	_	
20-24	3042-3047	those	_	_	
20-25	3048-3050	of	_	_	
20-26	3051-3056	other	_	_	
20-27	3057-3065	primates	_	_	
20-28	3066-3070	more	_	_	
20-29	3071-3078	closely	_	_	
20-30	3079-3083	than	_	_	
20-31	3084-3089	those	_	_	
20-32	3090-3092	of	_	_	
20-33	3093-3097	mice	_	_	
20-34	3097-3098	.	_	_	
20-35	3099-3100	[	_	_	
20-36	3100-3104	0189	_	_	
20-37	3104-3105	]	_	_	
20-38	3106-3117	Measurement	_	_	
20-39	3118-3120	of	_	_	
20-40	3121-3124	the	_	_	
20-41	3125-3135	activation	_	_	
20-42	3136-3138	of	_	_	
20-43	3139-3146	antigen	_	_	
20-44	3147-3157	presenting	_	_	
20-45	3158-3163	cells	_	_	
20-46	3164-3165	(	_	_	
20-47	3165-3168	APC	_	_	
20-48	3168-3169	)	_	_	
20-49	3170-3172	in	_	_	
20-50	3173-3181	response	_	_	
20-51	3182-3184	to	_	_	
20-52	3185-3197	immunization	_	_	
20-53	3198-3200	by	_	_	
20-54	3201-3208	antigen	_	_	
20-55	3209-3217	variants	_	_	
20-56	3218-3220	is	_	_	
20-57	3221-3228	another	_	_	
20-58	3229-3235	useful	_	_	
20-59	3236-3245	screening	_	_	
20-60	3246-3252	method	_	_	
20-61	3252-3253	.	_	_	

#Text=Induction of APC activation can be detected based on changes in surface expression levels of activation antigens, such as B7-1 (CD80), B7-2 (CD86), MHC class I and II, CD14, CD23, and Fc receptors, and the like.
#Text=[0190] Shuffled cancer antigens that induce cytotoxic T cells that have the capacity to kill cancer cells can be identified by measuring the capacity of T cells derived from immunized animals to kill cancer cells in vitro.
21-1	3254-3263	Induction	_	_	
21-2	3264-3266	of	_	_	
21-3	3267-3270	APC	_	_	
21-4	3271-3281	activation	_	_	
21-5	3282-3285	can	_	_	
21-6	3286-3288	be	_	_	
21-7	3289-3297	detected	_	_	
21-8	3298-3303	based	_	_	
21-9	3304-3306	on	_	_	
21-10	3307-3314	changes	_	_	
21-11	3315-3317	in	_	_	
21-12	3318-3325	surface	_	_	
21-13	3326-3336	expression	_	_	
21-14	3337-3343	levels	_	_	
21-15	3344-3346	of	_	_	
21-16	3347-3357	activation	_	_	
21-17	3358-3366	antigens	_	_	
21-18	3366-3367	,	_	_	
21-19	3368-3372	such	_	_	
21-20	3373-3375	as	_	_	
21-21	3376-3378	B7	_	_	
21-22	3378-3379	-	_	_	
21-23	3379-3380	1	_	_	
21-24	3381-3382	(	_	_	
21-25	3382-3386	CD80	_	_	
21-26	3386-3387	)	_	_	
21-27	3387-3388	,	_	_	
21-28	3389-3391	B7	_	_	
21-29	3391-3392	-	_	_	
21-30	3392-3393	2	_	_	
21-31	3394-3395	(	_	_	
21-32	3395-3399	CD86	_	_	
21-33	3399-3400	)	_	_	
21-34	3400-3401	,	_	_	
21-35	3402-3405	MHC	_	_	
21-36	3406-3411	class	_	_	
21-37	3412-3413	I	_	_	
21-38	3414-3417	and	_	_	
21-39	3418-3420	II	_	_	
21-40	3420-3421	,	_	_	
21-41	3422-3426	CD14	_	_	
21-42	3426-3427	,	_	_	
21-43	3428-3432	CD23	_	_	
21-44	3432-3433	,	_	_	
21-45	3434-3437	and	_	_	
21-46	3438-3440	Fc	_	_	
21-47	3441-3450	receptors	_	_	
21-48	3450-3451	,	_	_	
21-49	3452-3455	and	_	_	
21-50	3456-3459	the	_	_	
21-51	3460-3464	like	_	_	
21-52	3464-3465	.	_	_	
21-53	3466-3467	[	_	_	
21-54	3467-3471	0190	_	_	
21-55	3471-3472	]	_	_	
21-56	3473-3481	Shuffled	_	_	
21-57	3482-3488	cancer	_	_	
21-58	3489-3497	antigens	_	_	
21-59	3498-3502	that	_	_	
21-60	3503-3509	induce	_	_	
21-61	3510-3519	cytotoxic	_	_	
21-62	3520-3521	T	_	_	
21-63	3522-3527	cells	_	_	
21-64	3528-3532	that	_	_	
21-65	3533-3537	have	_	_	
21-66	3538-3541	the	_	_	
21-67	3542-3550	capacity	_	_	
21-68	3551-3553	to	_	_	
21-69	3554-3558	kill	_	_	
21-70	3559-3565	cancer	_	_	
21-71	3566-3571	cells	_	_	
21-72	3572-3575	can	_	_	
21-73	3576-3578	be	_	_	
21-74	3579-3589	identified	_	_	
21-75	3590-3592	by	_	_	
21-76	3593-3602	measuring	_	_	
21-77	3603-3606	the	_	_	
21-78	3607-3615	capacity	_	_	
21-79	3616-3618	of	_	_	
21-80	3619-3620	T	_	_	
21-81	3621-3626	cells	_	_	
21-82	3627-3634	derived	_	_	
21-83	3635-3639	from	_	_	
21-84	3640-3649	immunized	_	_	
21-85	3650-3657	animals	_	_	
21-86	3658-3660	to	_	_	
21-87	3661-3665	kill	_	_	
21-88	3666-3672	cancer	_	_	
21-89	3673-3678	cells	_	_	
21-90	3679-3681	in	_	_	
21-91	3682-3687	vitro	_	_	
21-92	3687-3688	.	_	_	

#Text=Typically the cancer cells are first labeled with radioactive isotopes and the release of radioactivity is an indication of tumor cell killing after incubation in the presence of T cells from immunized animals.
22-1	3689-3698	Typically	_	_	
22-2	3699-3702	the	_	_	
22-3	3703-3709	cancer	_	_	
22-4	3710-3715	cells	_	_	
22-5	3716-3719	are	_	_	
22-6	3720-3725	first	_	_	
22-7	3726-3733	labeled	_	_	
22-8	3734-3738	with	_	_	
22-9	3739-3750	radioactive	_	_	
22-10	3751-3759	isotopes	_	_	
22-11	3760-3763	and	_	_	
22-12	3764-3767	the	_	_	
22-13	3768-3775	release	_	_	
22-14	3776-3778	of	_	_	
22-15	3779-3792	radioactivity	_	_	
22-16	3793-3795	is	_	_	
22-17	3796-3798	an	_	_	
22-18	3799-3809	indication	_	_	
22-19	3810-3812	of	_	_	
22-20	3813-3818	tumor	_	_	
22-21	3819-3823	cell	_	_	
22-22	3824-3831	killing	_	_	
22-23	3832-3837	after	_	_	
22-24	3838-3848	incubation	_	_	
22-25	3849-3851	in	_	_	
22-26	3852-3855	the	_	_	
22-27	3856-3864	presence	_	_	
22-28	3865-3867	of	_	_	
22-29	3868-3869	T	_	_	
22-30	3870-3875	cells	_	_	
22-31	3876-3880	from	_	_	
22-32	3881-3890	immunized	_	_	
22-33	3891-3898	animals	_	_	
22-34	3898-3899	.	_	_	

#Text=Such cytotoxicity assays are known in the art.
23-1	3900-3904	Such	_	_	
23-2	3905-3917	cytotoxicity	_	_	
23-3	3918-3924	assays	_	_	
23-4	3925-3928	are	_	_	
23-5	3929-3934	known	_	_	
23-6	3935-3937	in	_	_	
23-7	3938-3941	the	_	_	
23-8	3942-3945	art	_	_	
23-9	3945-3946	.	_	_	
